GDF15 Cuts Liver Inflammation Without Weight Loss, Slowing Scarring in MASH

1 articles · Updated · ScienceDaily · Aug 21

Cell Metabolism data published Aug. 10 show GDF15 reduced liver inflammation and slowed fibrosis in mouse models of MASH even when food intake, body weight and liver fat did not change.
McMaster researchers traced that effect to a newly identified brain-to-liver pathway in which GDF15 triggers glucocorticoid release, suppressing immune activity and shifting liver cells into a less inflammatory state.
The finding challenges the view that GDF15's benefits mainly come from appetite suppression and weight loss, and suggests liver inflammation could be targeted directly alongside obesity-focused treatments.
MASH affects millions and can progress to cirrhosis, liver cancer and liver failure; the study points to a potential new treatment strategy for advanced fatty liver disease where inflammation can persist after weight loss.